V

    Volitionrx Ltd (VNRX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $0.43
    -0.02 (-5.19%)

    Market Cap: $6.48M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(25/40)
    Avg Surprise
    -11.81%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.31
    Range$-0.31 - $-0.31
    1 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.70-125.8%
    60d ago$-0.58-87.1%
    30d ago$-0.58-87.1%
    7d ago$-0.58-87.1%
    Current$-0.31
    Revenue Consensus
    $547330
    Range$462000 - $600000
    3 analysts
    Dec 31, 2026
    EPS Consensus$-0.29
    Range$-0.29 - $-0.29
    1 analysts
    Revenue Consensus
    $1M
    Range$894410 - $1M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.29---
    Sep 26EST
    		-$-0.31---
    Jun 26
    		$-0.78$-0.68-14.71%Miss+40.5%
    Mar 26
    		$-0.97$-0.73-32.88%Miss-1516.7%
    Dec 25
    		$-0.05$-0.05+2.78%Beat+96.2%
    Sep 25
    		$-1.06$-1.04-1.92%Miss+24.3%
    Jun 25
    		$-1.31$-1.00-31.00%Miss+18.1%
    Mar 25
    		$-0.06$-0.06+0.00%Beat+97.0%
    Dec 24
    		$-1.20$-1.07-12.15%Miss-990.9%
    Sep 24
    		$-1.40$-1.30-7.69%Miss+34.6%
    Jun 24
    		$-1.60$-1.85+13.51%Beat+42.9%
    Mar 24
    		$-2.00$-2.15+6.98%Beat+33.3%
    Dec 23
    		$-0.11$-0.11+0.00%Beat+15.4%
    Sep 23
    		$-2.14$-2.47+13.36%Beat+23.6%
    Jun 23
    		$-2.80$-2.87+2.44%Beat+0.0%
    Mar 23
    		$-3.00$-2.70-11.11%Miss-7.1%
    Dec 22
    		$-0.13$-0.15+13.33%Beat+13.3%
    Sep 22
    		$-2.80$-2.93+4.44%Beat-7.7%
    Jun 22
    		$-2.80$-2.87+2.44%Beat-34.6%
    Mar 22
    		$-2.80$0.90-411.11%Miss-16.7%
    Dec 21
    		$-0.15$-0.14-7.14%Miss-36.4%
    Sep 21
    		$-2.60$-2.07-25.60%Miss-34.7%
    Jun 21
    		$-2.08$-2.33+10.73%Beat+11.9%
    Mar 21
    		$-2.40$-2.27-5.73%Miss+14.3%
    Dec 20
    		$-0.11$-0.10-10.00%Miss+93.1%
    Sep 20
    		$-1.93$-2.20+12.27%Beat+3.5%
    Jun 20
    		$-2.36$-2.45+3.67%Beat-7.3%
    Mar 20
    		$-2.80$-1.93-45.08%Miss-16.7%
    Dec 19
    		$-1.60$-2.20+27.27%Beat-1354.5%
    Sep 19
    		$-2.00$-2.10+4.76%Beat+28.6%
    Jun 19
    		$-2.20$-2.27+3.08%Beat+26.7%
    Mar 19
    		$-2.40$-2.40+0.00%Beat+29.4%
    Dec 18
    		$-0.11$-0.13+15.38%Beat+26.7%
    Sep 18
    		$-2.80$-2.80+0.00%Beat+6.7%
    Jun 18
    		$-3.00$-3.00+0.00%Beat-15.4%
    Mar 18
    		$-3.40$-3.20-6.25%Miss-30.8%
    Dec 17
    		$-0.15$-0.16+6.25%Beat-25.0%
    Sep 17
    		$-3.00$-3.00+0.00%Beat+0.0%
    Jun 17
    		$-2.60$-2.80+7.14%Beat-
    Mar 17
    		$-2.60$-2.75+5.45%Beat-
    Dec 16
    		$-0.12$-0.13+7.69%Beat-
    Sep 16
    		$-3.00$-2.65-13.21%Miss-

    Key Metrics

    Valuation
    P/E Ratio-0.15EV/EBITDA-1.43x
    Price/FCF-0.30xFCF Yield-336.83%
    Profitability
    Profit Margin0.00%Operating Margin-1043.00%
    ROE-730.00%ROIC75.35%
    Financial Health
    Debt/Equity-0.33xInterest Coverage-3.88x
    Current Ratio0.30xQuick Ratio0.30x
    Trading Statistics
    Beta1.14Avg Volume21.83M
    52-Week High$14.8052-Week Low$0.33

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.43
    SMA 20$0.56
    SMA 50$0.92
    SMA 200$3.38
    EMA 10$0.46
    EMA 20$0.57
    EMA 50$0.97
    EMA 200$3.62

    MACD

    Line: -0.16Signal: -0.18Hist: 0.02

    ADX

    ADX: 37.1+DI: 21.4-DI: 27.9

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down88.0
    PSAR$0.34

    Bollinger Bands

    Upper Band$0.88
    Lower Band$0.25
    %B Position11187%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    31.8

    Momentum Oscillators

    Stoch %K28.7
    Stoch %D21.8
    Williams %R-77.9
    ROC (10d)-14.8%
    Momentum-0.07
    CCI (20d)-78.1
    MFI (14d)84.6

    Volatility Measures

    ATR (14d)$0.11(26.2%)
    StdDev (20d)0.16
    Hist Vol200.4%(High)

    Volume Flow

    VWAP$0.42
    OBV441.3M
    AD Line194.2B
    CMF (20d)-0.892

    Volume Metrics

    Avg Vol (20d)22.9M
    Vol Ratio0.2x(Low)
    VWMA (20d)$0.48

    Pivot Points

    R3$0.49
    R2$0.48
    R1$0.46
    Pivot Point$0.45
    S1$0.43
    S2$0.42
    S3$0.41

    Advanced Oscillators

    TSI-49.19
    Ultimate Osc32.3
    KST-529.42

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$398,657$985,076$447,034$627,277$406,688$246,385$194,595$474,522$395,797$168,597$243,973$165,211
    Cost of Revenue$0$0N/A$0$0$0$323,875$0$0$0$362,915$0
    Gross Profit$398,657$985,076$447,034$627,277$406,688$246,385$194,595$474,522$395,797$168,597$243,973$165,211
    Operating Expenses$4.55M$6.33M$5.26M$5.73M$6.70M$5.77M$5.97M$6.34M$7.39M$8.56M$8.97M$8.83M
    R&D$1.80M$2.85M$2.47M$2.29M$2.72M$2.61M$2.59M$3.47M$3.72M$4.63M$4.54M$4.65M
    SG&A$2.21M$2.63M$1.80M$2.48M$2.94M$2.24M$2.13M$1.82M$2.28M$2.25M$2.54M$2.60M
    Operating Income$-4,155,983$-5,348,852$-4,818,054$-5,100,990$-6,297,807$-5,521,720$-5,781,340$-5,868,707$-6,990,419$-8,384,504$-8,740,574$-8,653,055
    Interest Income$163$16$122$160$160$158$313$530$450$8,654$8,337$230
    Interest Expense$1.74M$1.59M$1.07M$873,430$448,661$96,669$92,491$89,456$81,182$77,233$57,999$53,980
    Income Before Tax$-7,315,604$-6,703,557$-6,304,670$-5,409,791$-6,314,400$-5,476,627$-5,788,648$-5,868,578$-7,060,175$-8,540,584$-8,815,613$-8,437,275
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,315,263$-6,703,557$-6,302,841$-5,409,791$-6,314,070$-5,476,627$-5,857,227$-5,868,578$-7,060,175$-8,472,005$-8,799,700$-8,453,188
    EBITDA$-4,884,204$-4,411,718$-4,051,436$-3,497,864$-5,222,051$-5,071,850$-5,344,353$-5,325,341$-6,769,012$-8,149,932$-8,402,657$-8,021,065
    EBIT$-5,574,811$-5,116,263$-5,234,213$-4,536,521$-5,865,899$-5,380,116$-5,696,470$-5,779,652$-6,979,443$-8,472,005$-8,765,951$-8,383,525
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about VNRX

    News

    VNRX Looks 97.8% Undervalued on GF Value™

    VolitionRX Ltd (AMEX: VNRX) appears significantly undervalued based on its Price-to-Sales ratio, despite ongoing unprofitability and financial challenges. The company recently published a peer-reviewed study highlighting the clinical relevance of its Nu.Q NETs H3.1 biomarker for sepsis prognosis. While insider buying suggests some confidence, investors should view VNRX as a speculative growth opportunity due to its high execution risks.

    GuruFocus•8/26/26•
    Neutral

    VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

    VolitionRx announced significant clinical and commercial progress in the first half of 2026, including 112% revenue growth and advancements in sepsis, lung cancer, and feline lymphoma diagnostics. The company is actively pursuing global licensing agreements and collaborations for its Nu.Q® and Capture-Seq™ platforms, targeting multi-billion dollar markets in human and animal health. Key achievements include validation of Nu.Q® NETs for sepsis, progress on lung cancer reimbursement in Europe, and a $5 million milestone anticipated for its feline cancer test.

    Yahoo Finance UK•8/26/26•
    Bullish

    Volition's sepsis biomarker predicts 28-day death and kidney treatment needs

    Volition (NYSE American: VNRX) announced that its Nu.Q® NETs H3.1 biomarker has been clinically validated as an independent predictor of 28-day mortality and the need for renal replacement therapy in sepsis and septic shock patients. The findings, published in Critical Care Medicine, highlight the biomarker's potential for early risk stratification and intervention, supporting Volition's ongoing licensing discussions within the estimated $2.8 billion sepsis diagnostics market. Despite the positive clinical news, Volition's stock experienced a decline, reflecting a negative market reaction.

    Stock Titan•8/26/26•
    Somewhat-Bearish

    VolitionRx Issues 773,361 Shares to Satisfy $400,000 Convertible Note Obligations

    VolitionRx Limited (NYSE American: VNRX) issued 773,361 shares of common stock to Lind Global Asset Management XII LLC to satisfy $400,000 in conversion obligations from its senior secured convertible promissory notes. This issuance involved 220,264 shares for a $150,000 obligation on August 11, 2026, and 553,097 shares for a $250,000 obligation on August 20, 2026. The company relied on exemptions under the Securities Act for this transaction, leading to an increase in outstanding shares which could impact stock price.

    Minichart•8/25/26•
    Somewhat-Bearish

    Maxim Group Maintains VolitionRX(VNRX.US) With Buy Rating

    Maxim Group has reiterated its Buy rating on VolitionRX (VNRX.US) stock. The analyst firm continues to show confidence in the company's prospects.

    Moomoo•8/19/26•
    Bullish

    Frequently Asked Questions About VNRX

    Does VNRX pay dividends?
    Volitionrx Ltd (VNRX) does not currently pay a regular dividend.
    What is VNRX's market cap?
    Volitionrx Ltd (VNRX) has a market capitalization of $6.48M with a current stock price of $0.43.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In